Surfactin Bacterial Antiviral Lipopeptide Blocks In Vitro Replication of SARS-CoV-2

Crovella, Sergio and de Freitas, Lucas Carvalho and Zupin, Luisa and Fontana, Francesco and Ruscio, Maurizio and Pena, Elton Pedro Nunes and Pinheiro, Irapuan Oliveira and Calsa Junior, Tercilio (2022) Surfactin Bacterial Antiviral Lipopeptide Blocks In Vitro Replication of SARS-CoV-2. Applied Microbiology, 2 (3). pp. 680-687. ISSN 2673-8007

[thumbnail of applmicrobiol-02-00052.pdf] Text
applmicrobiol-02-00052.pdf - Published Version

Download (2MB)

Abstract

Despite great efforts have been made worldwide, the coronavirus disease 19 (COVID-19) still has not a definitive cure, although the availability of different vaccines are slowing down the transmission and severity. It has been shown that surfactin, a cyclic lipopeptide produced by Bacillus subtilis, is a molecule able to counteract both SARS-CoV-1, MERS-CoV and HCoV-229E coronaviruses. In this study the potential antiviral activity of surfactin against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was tested in vitro in a cellular model of infection. Our results show that 2 h treatment with surfactin is able to reduce SARS-CoV-2 infectivity on Vero E6 cells both at 24 h and after 7 days from viral inoculation, probably impairing the viral membrane integrity. Moreover, surfactin, at the concentrations used in our experimental settings, is not cytotoxic. We suggest surfactin as a new potential molecule against SARS-CoV-2, to be employed at least as a disinfectant.

Item Type: Article
Subjects: Universal Eprints > Biological Science
Depositing User: Managing Editor
Date Deposited: 27 Jan 2023 05:05
Last Modified: 23 Feb 2024 03:42
URI: http://journal.article2publish.com/id/eprint/379

Actions (login required)

View Item
View Item